The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian Simvastatin Survival Study

Circulation

Volumn 101, Issue 12, 2000, Pages 1366-1371

  Gerdes, Lars Ulrik ^a   Gerdes, Christian ^a   Kervinen, Kari ^b   Savolainen, Markku ^b   Klausen, Ib Christian ^a   Hansen, Peter Steen ^a   Kesäniemi, Y Antero ^b   Færgeman, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apolipoproteins; Genetics; Mortality; Myocardial infarction; Prognosis

Indexed keywords

APOLIPOPROTEIN E4; SIMVASTATIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK; SURVIVAL; FOLLOW UP; GENETICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ALLELES; ANTILIPEMIC AGENTS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIMVASTATIN;

EID: 0034724089     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.12.1366     Document Type: Article

References (40)

1. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. N Engl J Med. 1998;338:122-124.
2. Davignon J. Gregg RE. Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
3. Hixson JE. Apolipoprotein E polymorphism affect atherosclerosis in young males. Arterioscler Thromb. 1991;11:1237-1244.
4. de Knijff P, Havekes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol. 1996;7:59-63.
5. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16:1250-1255.
6. Köhler E, Bentrup A, Funke H, Sandkamp M, Schulte H, Assmann G. Untersuchungen zur Beziehung zwischen Lipidstoffwechselstörungen und Erstmanifestationsalter der koronaren Herzkrankheit (KHK). Z Kardiol. 1992;81:354-360.
7. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary heart disease. Am J Cardiol. 1993;71:160-165.
8. Lehtinen S, Lehtimaki T, Sisto T, Salenius JP, Nikkila M, Jokela H, Koivula T, Ebeling F, Ehnholm C. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis. 1995;114:83-91.
9. Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
10. Wang XL, McCredie RM, Wilcken DEL. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol. 1995;15:1030-1034.
11. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J. 1987;113:433-440.
12. Dallongeville J, Lussier Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33:447-454.
13. Weisgraber KH. Apolipoprotein E: structure-function relationships. In: Schumaker VN, ed. Advances in Protein Chemistry. Vol 45. New York: Academic Press; 1994:249-302.
14. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993; 71:393-400.
15. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997;52:254-261.
16. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31: 545-548.
17. Hansen PS, Gerdes LU, Klausen IC, Gregersen N, Faergeman O. Genotyping compared with protein phenotyping of the common apolipoprotein E polymorphism. Clin Chim Acta. 1994;224:131-137.
18. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27:227-235.
19. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34: 187-202.
20. Kleinbaum DG. Survival Analysis. A Self-Learning Text. New York: Springer-Verlag; 1996.
21. Goldbourt U, Neufeld HN. Genetic aspects of arteriosclerosis. Arteriosclerosis. 1986;6:357-377.
22. Berg K. Impact of medical genetics on research and practices in the area of cardiovascular disease. Clin Genet. 1989;36:299-312.
23. Sing CF, Moll PP. Genetics of variability of CHD risk. Int J Epidemiol. 1989;18:S183-S195.
24. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia, Pa: . Lippincott-Raven Publishers; 1998:127-132.
25. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
26. Schroeder AP, Falk E. Vulnerable and dangerous coronary plaques. Atherosclerosis. 1995;118(suppl):S141-S149.
27. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation. 1996;94:2013-2020.
28. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
29. Damaraju S, Yu QT, Safavi F, Marian AJ. Apolipoprotein epsilon 4 is not a genetic risk factor for coronary artery disease or restenosis after per-cutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;75: 1181-1183.
30. van Bockxmeer FM, Mamotte CDS, Gibbons FA, Burke V, Taylor RR. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation. 1995;92:2066-2071.
31. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996;7:389-397.
32. Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH. Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis. 1996;118(suppl): S11-S27.
33. Ordovas JM, Lopez Miranda J, Perez Jimenez F. Rodriguez C, Park JS, Cole T, Schaefer EJ. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 1995;113:157-166.
34. Kobayashi T, Homma Y, Handa S, Nakamura H. Influence of apolipoprotein E phenotype on changes in plasma levels of low-density lipoprotein-cholesterol and apolipoprotein B due to the effects of simvastatin. Nutr Metab Cardiovasc Dis. 1998;8:358-364.
35. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
36. Weisgraber KH, Roses AD, Strittmatter WJ. The role of apolipoprotein E in the nervous system. Curr Opin Lipidol. 1994;5:110-116.
37. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol. 1996;7:303-307.
38. Higashihara M, Kinoshita M, Teramoto T. Kume S, Kurokawa K. The role of apoE in inhibitory effects of apoE-rich HDL on platelet function. FEBS Lett. 1991;282:82-86.
39. Loktionov A, Bingham SA, Vorster H, Jerling JC, Runswick SA, Cummings JH. Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study. Br J Nutr. 1998;79:133-139.
40. Lemming L. Klausen IC, Gerdes LU, Hansen PS, Faergeman O. Apolipoprotein(a) genotypes in a Scandinavian population: allele frequencies, correlation to apolipoprotein(a) phenotypes and lipoprotein(a) concentrations. Nutr Metab Cardiovasc Dis. 1997;7:1-7.